ACTRN12623000431628
Withdrawn
Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELVN-002 in Healthy Adult Volunteers, Part B: Open-label Food Effect
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Enliven Therapeutics, Inc.
- Enrollment
- 6
- Status
- Withdrawn
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male or female, aged more than 18 to less than 60 years old (both inclusive at the time of informed consent).
- •2\. In good general health, with no significant medical history, and no clinically significant abnormalities on physical examination at Screening and/or before the first administration of IP at the discretion of the PI or designee.
- •3\. Body mass index (BMI) greater than 18 and less than 32\.0 kg/m2 at Screening and weight more than 50 kg.
- •4\. Non\-smoker (has not used any tobacco products). A participant who smokes less than 2 cigarettes or equivalent (eg, cigars, vaping, nicotine patches) per week within 3 months prior to Screening can be included in the study if willing and able to stop smoking for the duration of the study, at the discretion of the PI or designee.
- •5\. Clinical laboratory values at Screening (including haematology, biochemistry, coagulation, and urinalysis) within normal range as specified by the testing laboratory, unless deemed not clinically significant by the PI or designee.
- •6\. Acceptable estimated glomerular filtration rate (eGFR) for the study using the Chronic Kidney Disease Epidemiology Collaboration (CKD\-EPI) creatinine equation: greater than 89 mL/min/1\.73 for participants 18 to 59 years old, or greater than 84 mL/min/1\.73 for participants 60 years old).
- •7\. Women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening and Day \-1 and be willing to have additional pregnancy tests as required throughout the study.
- •8\. Female participants who meet 1 of the following criteria will be included.
- •a. Female participants must not be pregnant or lactating, and must use acceptable, highly effective double contraception from Screening until 90 days after the last study procedure is completed. Females with same\-sex partners (abstinence from penile\-vaginal intercourse) or who are abstinent from heterosexual intercourse are not required to use contraception when this is their preferred and usual lifestyle. Effective forms of contraception include:
- •Simultaneous use of intrauterine device (IUD) (non\-hormonal) and condom for the male partner.
Exclusion Criteria
- •1\. Has participated in previous studies of ELVN\-002\.
- •2\. Underlying physical or psychological medical condition that, in the opinion of the PI, could impact on the participant’s safety, participant involvement in the study, or data integrity.
- •3\. History or surgical records of any clinically significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary, or gastrointestinal pathology, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the IP, as determined by the PI or designee.
- •4\. History of severe allergic or anaphylactic reactions, or sensitivity to ELVN\-002, itraconazole, and phenytoin, or their constituents.
- •5\. History of malignancy, except for non\-melanoma skin cancer, excised more than 2 years ago and cervical intraepithelial neoplasia that has been successfully cured more than 5 years prior to Screening (a general practitioner \[GP] letter or biopsy report for confirmation required).
- •6\. History of symptomatic bacterial or viral infection within 2 weeks prior to Screening.
- •7\. Abnormal ECG findings at Screening or Day \-1 (eg, repeated demonstration of a QTc interval greater than 450 ms (male) or greater than 470 ms (female) corrected by Fridericia's formula \[QTcF] or Bazett's formula \[QTcB]) that are considered by the PI or designee to be clinically significant.
- •8\. History of clinically significant arrhythmia, cardiac conditions, or risk factors for Torsades de Pointes (eg, heart failure, current hypokalaemia, and family history of long QT syndrome).
- •9\. Clinically significant findings in transthoracic echocardiogram at Screening, including less than normal left ventricular ejection fraction (LVEF).
- •10\. Blood donation or significant blood loss (greater than 500 mL) within 60 days prior to the first administration of IP.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Multiple ascending dose study of ALKS 7119NL-OMON27126Alkermes, Inc.48
Terminated
Phase 1
A study to evaluate safety and tolerability of GS -5801 in healthy subjectsHepatitis B VirusInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12616001260415Gilead Sciences, Inc.70
Withdrawn
Not Applicable
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Injection of ABT-110 in Healthy Volunteers and Subjects with Chronic Low Back Paichronic low back pain10028302NL-OMON36923Abbott30
Not yet recruiting
Not Applicable
A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 Combination Therapies in Subjects With Advanced Solid Tumorsadvanced solid tumor10017991NL-OMON37039Merck Sharp & Dohme (MSD)24
Recruiting
Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-4224 in Healthy Volunteers and Subjects with the Chronic Hepatitis B (CHB) VirusHepatitis BInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12618001957280Gilead Sciences, Inc210